CN117547578A - 一种降尿酸及治疗痛风的组合物及其制备方法 - Google Patents
一种降尿酸及治疗痛风的组合物及其制备方法 Download PDFInfo
- Publication number
- CN117547578A CN117547578A CN202311574021.XA CN202311574021A CN117547578A CN 117547578 A CN117547578 A CN 117547578A CN 202311574021 A CN202311574021 A CN 202311574021A CN 117547578 A CN117547578 A CN 117547578A
- Authority
- CN
- China
- Prior art keywords
- parts
- uric acid
- composition
- gout
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 90
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229940116269 uric acid Drugs 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 201000005569 Gout Diseases 0.000 title claims abstract description 46
- 230000001603 reducing effect Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 235000021028 berry Nutrition 0.000 claims abstract description 34
- 241000533293 Sesbania emerus Species 0.000 claims abstract description 33
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 32
- 235000021537 Beetroot Nutrition 0.000 claims abstract description 31
- 241000219745 Lupinus Species 0.000 claims abstract description 29
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 claims abstract description 24
- 229940109850 royal jelly Drugs 0.000 claims abstract description 24
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims description 36
- 239000000284 extract Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000007788 liquid Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 8
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 241000219991 Lythraceae Species 0.000 claims 7
- 244000294611 Punica granatum Species 0.000 abstract description 25
- 230000000694 effects Effects 0.000 abstract description 24
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 22
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 14
- 108010093894 Xanthine oxidase Proteins 0.000 description 13
- 102100033220 Xanthine oxidase Human genes 0.000 description 13
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 10
- 201000001431 Hyperuricemia Diseases 0.000 description 10
- 210000003734 kidney Anatomy 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229920002079 Ellagic acid Polymers 0.000 description 7
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 7
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 229940109239 creatinine Drugs 0.000 description 7
- 229960002852 ellagic acid Drugs 0.000 description 7
- 235000004132 ellagic acid Nutrition 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000208368 Euonymus alatus Species 0.000 description 6
- 229960003459 allopurinol Drugs 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940075420 xanthine Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 235000016614 betalains Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- 102000055025 Adenosine deaminases Human genes 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 244000298479 Cichorium intybus Species 0.000 description 2
- 235000007542 Cichorium intybus Nutrition 0.000 description 2
- 240000007154 Coffea arabica Species 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241001083505 Punica Species 0.000 description 2
- 206010061481 Renal injury Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000001556 apium graveolens l. seed extract Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940116732 celery seed extract Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- -1 small molecule phenolic compound Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WXBXVVIUZANZAU-UHFFFAOYSA-N 2E-decenoic acid Natural products CCCCCCCC=CC(O)=O WXBXVVIUZANZAU-UHFFFAOYSA-N 0.000 description 1
- OLUUSIGKTFFDPM-UHFFFAOYSA-N 2h-oxazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CON1 OLUUSIGKTFFDPM-UHFFFAOYSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102000010722 N-Glycosyl Hydrolases Human genes 0.000 description 1
- 108010063372 N-Glycosyl Hydrolases Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000005805 Prunus cerasus Nutrition 0.000 description 1
- 244000207449 Prunus puddum Species 0.000 description 1
- 235000009226 Prunus puddum Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010092464 Urate Oxidase Proteins 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940069765 bean extract Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- JXOHGGNKMLTUBP-HSUXUTPPSA-N shikimic acid Chemical compound O[C@@H]1CC(C(O)=O)=C[C@@H](O)[C@H]1O JXOHGGNKMLTUBP-HSUXUTPPSA-N 0.000 description 1
- JXOHGGNKMLTUBP-JKUQZMGJSA-N shikimic acid Natural products O[C@@H]1CC(C(O)=O)=C[C@H](O)[C@@H]1O JXOHGGNKMLTUBP-JKUQZMGJSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- WXBXVVIUZANZAU-CMDGGOBGSA-N trans-2-decenoic acid Chemical compound CCCCCCC\C=C\C(O)=O WXBXVVIUZANZAU-CMDGGOBGSA-N 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种降尿酸及治疗痛风的组合物及其制备方法,所述组合物的制备原料包括:蜂王浆100‑150份、巴西莓100‑150份、宝乐果90‑140份、绿咖啡豆90‑140份、石榴90‑140份、红甜菜根90‑140份以及羽扇豆60‑90份。本发明的组合物将七种组分进行复合搭配,显著发挥协同增效作用,相比于现有市售制品或类似组合物具有显著的降尿酸及治疗痛风的效果,且本发明组合物持续食用不会产生耐药性,服用1个月后具有显著的降尿酸效果,调整到正常尿酸水平后,停用一段时间后,尿酸值仍然稳定不会反弹。
Description
技术领域
本发明涉及保健食品及药品组合物技术领域,具体涉及一种降尿酸及治疗痛风的组合物及其制备方法。
背景技术
痛风是由于嘌呤类物质代谢紊乱,产生尿酸过多和(或)尿酸排泄减少,血尿酸浓度持续增高,导致尿酸盐结晶沉积软组织所致的一组代谢性疾病。高尿酸血症是痛风最重要的生化基础。随着人们生活水平的不断提高和饮食结构的改变,痛风和高尿酸血症的患病率在全球范围呈逐年上升的趋势,我国高尿酸血症的总体患病率为 13.3%,患病人群约1.77亿。现有的用于治疗痛风的药物副作用比较多,如临床使用较多的别嘌呤醇、非布司他,有发热、过敏、胃肠反应、荨麻疹、头痛、肾功能损伤、肝坏死等不良反应。而且,化学药物具有很强的耐药性,在停药后尿酸容易反弹,因此,人们更希望采用药食两用的产品进行持续降尿酸,制造一种即可融尿酸结石又可降尿酸的配方,可将痛风危害减到最低限度是十分有必要的。
发明内容
基于现有技术存在的缺陷,本发明的目的在于提供了一种具有降尿酸及治疗痛风的组合物,该产品的组分中包含蜂王浆,巴西莓,宝乐果,绿咖啡豆,石榴、红甜菜根、羽扇豆,七种组分经过协同作用可实现降尿酸以及治疗痛风的显著效果。
为了实现以上目的,本发明采取的技术方案为:
一种降尿酸及治疗痛风的组合物,按重量份计,其制备原料包括:蜂王浆100-150份、巴西莓100-150份、宝乐果90-140份、绿咖啡豆90-140份、石榴90-140份、红甜菜根90-140份以及羽扇豆60-90份。
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经乙醇水溶液提取后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水提取后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
优选的,按重量份计,所述组合物的制备原料包括:蜂王浆120-140份、巴西莓120-140份、宝乐果100-130份、绿咖啡豆110-130份、石榴110-130份、红甜菜根100-130份以及羽扇豆70-80份。
优选的,按重量份计,所述组合物的制备原料包括:蜂王浆100-130份、巴西莓130-150份、宝乐果90-130份、绿咖啡豆110-140份、石榴110-140份、红甜菜根90-130份以及羽扇豆60-80份。
优选的,按重量份计,所述组合物的制备原料包括:蜂王浆130-150份、巴西莓100-130份、宝乐果120-140份、绿咖啡豆90-130份、石榴90-130份、红甜菜根100-140份以及羽扇豆80-90份。
以上原料的功效为:
蜂王浆:蜂王浆富含活性成分王浆主蛋白,一方面王浆主蛋白可通过抑制黄嘌呤氧化酶活性,抑制嘌呤转化为尿酸,从而从源头上减少尿酸的生成;另一方面王浆主蛋白可抑制肾脏对尿酸的重吸收,帮助人体内的尿酸加速从肾脏排泄,从而可以降低体内的尿酸水平。此外,蜂王浆还富含活性成分癸烯酸,具有较强的抗炎作用,改善肾小球炎症,提高肾小球正常过滤屏障功能,发挥正常尿酸排泄。
巴西莓:巴西莓是生长在亚马逊流域的阿萨伊棕榈树的果实,其含有丰富的多酚类、黄酮类等物质,具有保护细胞、减少内源性尿酸生成等功能。巴西莓含有的以儿茶素为代表的多酚类物质和黄酮类物质具有降尿酸作用,能抑制黄嘌呤氧化酶活性、腺苷脱氨酶活性,从而减少尿酸的产生,并且能显著降低血清中尿素氮、肌酐水平,作用效果优于别嘌呤醇,对肾脏具有保护作用,能够实现降尿酸、修复肝肾、恢复尿酸代谢平衡的整体功能。此外,巴西莓富含的Omega-3(α-亚麻酸)可通过使尿酸合成减少,不易沉淀在关节部位,不发生炎症而起到预防痛风、减少痛风发作频率和程度的作用。
宝乐果:新鲜宝乐果含有丰富的B族维生素,其维生素B2远高于大多数水果,且烟酸含量也高于其它热带水果。人体摄入嘌呤过多或内源性嘌呤生成过多时会引起大量尿酸生成。嘌呤会经核苷酶分解为次黄嘌呤,后者经过黄嘌呤氧化酶作用代谢为黄嘌呤,经进一步代谢最终形成大量尿酸。而叶酸等B族维生素可以通过降低黄嘌呤氧化酶产生氧自由基及过氧化物的能力,抑制黄嘌呤氧化酶的活性,从而同时减少血清尿酸生成。此外,腺苷脱氨酶也是嘌呤核苷代谢中重要的酶类,其代谢终产物为尿酸。维生素B2可以通过降低腺苷脱氨酶活性从而达到降低血尿酸生成的效果。
绿咖啡豆:绿咖啡豆是咖啡豆的一种,是指从咖啡树上采摘而来,未经烘焙的咖啡豆。相比烘焙过的咖啡豆,绿咖啡豆保留大量的营养成分。绿原酸类物质是绿咖啡豆提取物中的主要活性成分,产生于植物体内有氧呼吸过程,是一种经莽草酸途径产生的苯丙素类次生代谢产物。绿原酸具有广泛的生物活性。研究结果表明,绿咖啡豆水提取物可以通过尿酸稳态途径起到降尿酸作用。同时,每100g绿咖啡中的嘌呤含量大约在19mg左右,属于低嘌呤食物,对于高尿酸血症或者痛风的患者能够起到辅助治疗的作用。
红甜菜根:红甜菜根属于根茎类,这种根茎类蔬菜含有丰富的微量元素,同时还含有丰富的维生素C。维生素C能够促进尿酸盐的溶解,有利于尿酸的的排泄,预防泌尿结石的形成。更值得一提的是,高尿酸血症与肾小管损伤、巨噬细胞浸润和炎症介质表达增加有关,而红甜菜根中所含的芸香素等成分,能抑制脂质过氧化,稳定细胞膜和钙离子水平,通过改善肾脏有效血浆流量,提高肾小球滤过率,从而改善肾功能、预防和治疗肾损伤。此外,红甜菜含有高浓度的甜菜红素。而且,甜菜红素是一种极佳的抗氧化剂,能帮助尿酸的肾排泄,同时也有保护肾脏的作用。中医认为痛风急性发作的原因之一在于血淤,而“血行风自灭”,甜菜红素还可以改善血液的循环情况,因此在痛风的急性发作时,甜菜红素可以起到一定的止痛作用。
石榴:石榴为石榴科石榴属,原产于伊朗及其周边地区,我国各地都有栽培。石榴中富含鞣花但宁、鞣花酸等植物化学物质。胃肠道虽不能直接吸收石榴中存在的鞣花但宁,但它们会自发参与水解,产生鞣花酸及其衍生物。研究表明,与其他水果相比,从石榴提取物中分离的鞣花酸具有更好的生物利用度和生物活性。鞣花酸是一种天然小分子酚类化合物和天然类黄酮,是一种有效的黄嘌呤氧化酶抑制剂和超氧阴离子清除剂。鞣花酸能够通过抑制黄嘌呤氧化酶的活性、蛋白表达,以及增加尿酸排泄两个方面起到降低血清尿酸水平的效果。同时鞣花酸可以通过调节NLRP3炎症小体途径来减轻高尿酸血症诱导的肝肾酸伤及痛风性水肿症状,例如足肿胀等。
羽扇豆:羽扇豆中富含活性成分羽扇豆碱,属于活性生物碱,具有弱碱性特征,增加体液尿酸溶解度,保护肾脏功能,促进排泄,从而有效抑制机体的血尿酸水平升高。
优选的,步骤(2)所述乙醇水溶液的体积分数为50%~80%。
优选的,步骤(2)中,提取料液比为1:5-1:10,提取温度50-80℃,提取时间为1-4h。
优选的,步骤(3)中,提取料液比为1:8-1:20,提取温度60-90℃,提取时间为2-6h。本发明还提供了所述组合物在制备降尿酸或治疗痛风的食品或药物中的应用。优选的,所述食品的剂型为片剂、粉剂、胶囊剂、丸剂、口服液、饮料或者软糖。优选的,所述食品由所述组合物以及食品中可接受的辅料制成。优选的,所述食品为保健食品。
与现有技术相比,本发明的有益效果在于:
本发明提供了降尿酸及治疗痛风的组合物,该产品将蜂王浆、巴西莓、宝乐果、绿咖啡豆、石榴、红甜菜根以及羽扇豆,七种组分进行复合搭配,显著发挥协同增效作用,相比于现有市售制品或类似组合物具有显著的降尿酸及治疗痛风的效果,通过动物模型实验和人体试食实验后均可证实该产品的功效性。本发明持续食用不会产生耐药性,服用1个月后具有显著的降尿酸效果,调整到正常尿酸水平后,停用一段时间后,尿酸值仍然稳定不会反弹。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
一种降尿酸及治疗痛风的组合物,按重量份计,其制备原料包括:
蜂王浆120份、巴西莓140份、宝乐果130份、绿咖啡豆110份、石榴140份、红甜菜根90份以及羽扇豆70份。
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经50%体积分数乙醇水溶液以料液比1:10在70℃下提取2h后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水以料液比1:10在80℃下提取6h后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
实施例2
一种降尿酸及治疗痛风的组合物,按重量份计,其制备原料包括:
蜂王浆100份、巴西莓150份、宝乐果100份、绿咖啡豆140份、石榴110份、红甜菜根130份以及羽扇豆60份。
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经60%体积分数乙醇水溶液以料液比1:8在80℃下提取1h后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水以料液比1:15在70℃下提取4h后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
实施例3
一种降尿酸及治疗痛风的组合物,按重量份计,其制备原料包括:
蜂王浆150份、巴西莓100份、宝乐果140份、绿咖啡豆90份、石榴120份、红甜菜根120份以及羽扇豆90份。
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经70%体积分数乙醇水溶液以料液比1:6在50℃下提取2h后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水以料液比1:8在90℃下提取5h后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
实施例4
一种降尿酸及治疗痛风的组合物,按重量份计,其制备原料包括:
蜂王浆140份、巴西莓120份、宝乐果120份、绿咖啡豆130份、石榴90份、红甜菜根140份以及羽扇豆80份。
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经80%体积分数乙醇水溶液以料液比1:7在60℃下提取3h后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水以料液比1:20在60℃下提取2h后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
实施例5
一种降尿酸及治疗痛风的组合物,按重量份计,其制备原料包括:
蜂王浆130份、巴西莓130份、宝乐果90份、绿咖啡豆120份、石榴130份、红甜菜根100份以及羽扇豆80份。
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经75%体积分数乙醇水溶液以料液比1:5在60℃下提取4h后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水以料液比1:18在70℃下提取3h后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
对比例1
本对比例与实施例1的区别在于:采用等重量份数的西芹籽提取物替代蜂王浆。
对比例2
本对比例与实施例1的区别在于:采用等重量份数的酸樱桃替代巴西莓。
对比例3
本对比例与实施例1的区别在于:采用等重量份数的栀子替代绿咖啡豆。
对比例4
本对比例与实施例1的区别在于:采用等重量份数的菊苣替代宝乐果。
对比例5
本对比例与实施例1的区别在于:采用等重量份数的姜黄替代羽扇豆。
对比例6
本对比例与实施例1的区别在于:同时采用等重量份数的西芹籽提取物替代蜂王浆,等重量份数的酸樱桃替代巴西莓,等重量份数的栀子替代绿咖啡豆,等重量份数的菊苣替代宝乐果,等重量份数的姜黄替代羽扇豆。
一、本发明的组合物对黄嘌呤氧化酶的抑制率实验
1、溶液的配置
(1)0.2mol/L(pH7.5)磷酸缓冲液(PBS):准确称取30.0838g Na2HPO4·12H2O和2.4962g NaH2PO4·2H2O,用去离子水溶解,定容至500mL。
(2)黄嘌呤溶液:准确称取6.4mg黄嘌呤,先用1mL 1M NaOH将其溶解,再加入100mLPBS,以1MHCl调节pH值至7.5。
(3)黄嘌呤氧化酶:取120μl酶液,以PBS稀释至8mL。
(4)尿酸标准曲线溶液:准确称取10mg尿酸,加入10mL水,再稀释至0.1、0.3、0.5、0.7及0.9mg/mL的尿酸溶液,超声离心处理完成后,进行高效液相分析。
(5)醋酸胺-冰醋酸溶液:准确称取醋酸胺3.85g加水定容至1000mL,然后加入4mL冰醋酸。
2、样品预处理:
将实施例1-5和对比例1-6制得的组合物样品用PBS稀释至40mg/mL得样品液体,实验组在96孔酶标板中依次加入50μL样品液体与50μL黄嘌呤溶液,每个样品做3个平行,37℃保温10min后加入150μL黄嘌呤氧化酶,37℃继续保温20min后加入80μL1M HCl终止反应,过0.25μm水性膜,待测。对照组在96孔酶标板中依次加入50μL PBS与50μL黄嘌呤溶液,其余操作与实验组一样。
3、高效液相色谱测试:
将样品预处理后的实验组和对照组取样,超声离心处理完成后,分别进行高效液相色谱测试分析,条件如下:
色谱柱:ZorbaxEclipseXDB-C18柱(5μm,4.6×250mm,安捷伦)。
液相条件:洗脱液为10%甲醇+90%醋酸胺-冰醋酸溶液,进样体积为20μL,流速1mL/min,检测波长为290nm,运行时间10min。
4、计算公式
黄嘌呤氧化酶抑制率=。
式中:
A0——对照组进行高效液相色谱分析的尿酸峰的峰面积;
A——实验组进行高效液相色谱分析的尿酸峰的峰面积。
表1
由表1结果可知,各实施例组对黄嘌呤氧化酶抑制率较好,均达到30%以上,说明本发明的组合物具有显著的降尿酸的潜力。与实施例1相比,对比例1-6分别改变组合物中的制备原料后,其对黄嘌呤氧化酶抑制率表现一般均在30%以下,说明改变本发明的组合物的任一组分,将会影响组合物对黄嘌呤氧化酶抑制率。
二、本发明的组合物的降尿酸效果评价
1、试验方法
采用尿酸酶抑制剂氧嗪酸钾诱导建立高尿酸血症小鼠模型,首先将昆明雄性小鼠随机分为14组,分别为:空白组,模型组,实施例组(实施例1-5组合物给药)共计5组(200mg/kg•bw)和对比例组(对比例1-6组合物给药)共计6组(200mg/kg•bw)、别嘌呤醇阳性对照组(5mg/kg•bw),每组10只小鼠。在保证正常饮食饮水的条件下,空白组腹腔注射等体积生理盐水,其他各组腹腔注射250mg/kg•bw氧嗪酸钾(混悬于质量分数0.5% CMC-Na溶液中),连续给药7天。同时,实施例组和对比例组灌胃相应的剂量为200mg/kg•bw组合物(溶于质量分数0.9%的生理盐水,阳性组小鼠灌胃的剂量为5mg/kg•bw别嘌呤醇(溶于质量分数0.9%生理盐水),空白组和模型组灌胃与实施例同剂量0.9%生理盐水溶液,连续灌胃7天。第7日结束灌胃后对小鼠处以12h禁食处理,以便第7天灌胃结束后进行检测样品的提取工作。
2、脏器指数的测定
在第7天灌胃前12小时对所有小鼠进行断粮。称量小鼠的体重,在第7天灌胃结束后,摘眼球取血,断颈处死小鼠。取出其肝脏、肾脏组织,在4℃预冷的生理盐水中漂洗干净后称重,并计算脏器指数。结果见表2。
3、小鼠血清尿酸(UA)、尿素氮(BUN)、肌酐(Cr)含量的测定
连续灌胃7天后摘眼球取血,断颈处死小鼠。血液在室温条件下自然凝血1h后于4℃温度下3500rpm离心10min,取其上清液即得血清,将血清分装后放置于-20℃冷冻保存,备用。采用尿酸测试盒、尿素氮测试盒及肌酐测试盒来测定小鼠血清尿酸、尿素氮和肌酐的含量。结果见表3。
表2
注:与空白组比较, *差异显著(P<0.05), **差异极显著(P<0.01);与模型组比较,#差异显著(P<0.05),##差异极显著(P<0.01);与实施例1组比较,∆差异显著(P<0.05),∆∆差异极显著(P<0.01)。
由表2结果可知,模型组小鼠相较于空白组的肝/肾系数均极显著升高(P<0.01),说明腹腔注射氧嗪酸钾可引起小鼠肝脏和肾脏肿大,高尿酸血症小鼠模型造模成功。各实施例组相比模型组肝/肾系数均极显著降低(P<0.01),说明本发明组合物可缓解氧嗪酸钾诱导的高尿酸肝肾损伤。对比例1-6组相比模型组肝/肾系数显著降低(P<0.05,P<0.01),但降低效果显著低于实施例1(P<0.05,P<0.01),说明改变本发明的组合物的任一组分,对降低小鼠肝/肾系数的效果产生显著差异。
表3
注:与空白组比较, *差异显著(P<0.05), **差异极显著(P<0.01);与模型组比较,#差异显著(P<0.05),##差异极显著(P<0.01);与实施例1组比较,∆差异显著(P<0.05),∆∆差异极显著(P<0.01)。
由表3结果可知,模型组小鼠相较于空白组的血清尿酸值、尿素氮、肌酐均极显著升高(P<0.01),进一步说明腹腔注射氧嗪酸钾后高尿酸血症小鼠模型造模成功。各实施例组相比模型组血清尿酸值、尿素氮、肌酐均显著降低(P<0.05,P<0.01),说明本发明组合物具有显著降尿酸的作用。各对比例相比实施例1组血清尿酸值、尿素氮、肌酐均显著降低(P<0.05,P<0.01),说明改变本发明的组合物的任一组分,对小鼠降尿酸效果具有显著影响。
三、本发明的组合物的痛风改善评价
1、人体试验纳入标准:①符合 2015 年 ACR/EULAR 痛风分类标准。②血尿酸值≥480μmol/L。
具备以上2条,年龄范围在 18~65 岁者。
2、试验方法:以上人群120人,分为12组,每组10人,每组男女各一半,分别为实施例1-5组,对比例1-6组,阳性对照别嘌醇片组。考察1个月,实施例和对比例每人每日食用该组合物1g,每日1次,阳性对照组每日食用别嘌醇片0.1g,每日1次。常规饮食干预如下:
①饮食:禁止烟酒、软饮料,低嘌呤饮食嘌呤含量<75mg/100g;
②基础治疗:碳酸氢钠,每次 100 mg,每日 3 次,pH<6.0 时使用,保持 pH 在6.5~6.8,尿量每日>2000 mL,患者痛风急性发作不能控制时,应给予依托考昔片,60mg,每日1 次;
③保持生活规律。
(3)安全性及有效性评价
安全性指标考察食用前后的体重变化、不良反应情况(胃肠道不适、肝肾功能损害、皮疹等不良反应等),有效性评价考察空腹血尿酸水平变化、痛风中医证候评分变化。结果分别见表4。
表4
注:治疗30日后与治疗前比较,*体重差异显著(P<0.05),**体重差异极显著(P<0.01);
治疗30日后与治疗前比较,#尿酸差异显著(P<0.05),##尿酸差异极显著(P<0.01);
治疗30日后与治疗前比较,∆痛风中医证候评分差异显著(P<0.05),∆∆痛风中医证候评分差异极显著(P<0.01);
停止治疗后15日与治疗30日后比较,●差异显著(P<0.05),●●差异极显著(P<0.01)。
如表4所示,各实施例组产品服用1个月后,体重变化不显著(P>0.05),无不良反应,说明本发明产品食用安全。治疗后各实施例组的尿酸极显著降低(P<0.01),痛风中医证候评分极显著降低(P<0.01),而且在停止治疗15日后与之前对比,尿酸与治疗后30日数值差异不大(P>0.05),数值仍处在安全值范围内,痛风中医证候评分也无显著差异(P>0.05),说明本发明组合物对于降尿酸及治疗痛风效果稳定,停止治疗后不会反弹。
各对比例治疗后相比实施例的效果一般,其中对比例6(替换本发明的蜂王浆、巴西莓、咖啡豆、宝乐果、羽扇豆)治疗前后对尿酸值及痛风中医证候评分差异不显著(P>0.05),说明改变本发明组合物的组分,将无法发挥各组合物之间的协同作用,对人体降尿酸效果及治疗痛风的效果有显著影响。而且,在停止治疗15日后与之前对比,尿酸与治疗后30日数值差异显著(P<0.05),进一步说明本发明组合物的各组分之间具有协同作用,改变本发明的任一组分将影响降尿酸的效果、治疗痛风的疗效。
最后应说明的是,以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种降尿酸及治疗痛风的组合物,其特征在于,按重量份计,所述组合物的制备原料包括:蜂王浆100-150份、巴西莓100-150份、宝乐果90-140份、绿咖啡豆90-140份、石榴90-140份、红甜菜根90-140份以及羽扇豆60-90份;
所述组合物的制备包括以下步骤:
(1)将蜂王浆加水解冻,经冷冻干燥后成粉末;
(2)将巴西莓、宝乐果、石榴和红甜菜根清洗、破碎,经乙醇水溶液提取后过滤,得混合提取液1,所述混合提取液1经冷冻干燥得混合冻干粉1;
(3)将绿咖啡豆、羽扇豆粉碎,经压榨去油获得豆渣,经水提取后过滤,得混合提取液2,所述混合提取液2经冷冻干燥得混合冻干粉2;
(4)将以上处理得到的混合冻干粉1和混合冻干粉2混合,即得所述组合物。
2.根据权利要求1所述的降尿酸及治疗痛风的组合物,其特征在于,按重量份计,所述组合物的制备原料包括:蜂王浆120-140份、巴西莓120-140份、宝乐果100-130份、绿咖啡豆110-130份、石榴110-130份、红甜菜根100-130份以及羽扇豆70-80份。
3.根据权利要求1所述的降尿酸及治疗痛风的组合物,其特征在于,按重量份计,所述组合物的制备原料包括:蜂王浆100-130份、巴西莓130-150份、宝乐果90-130份、绿咖啡豆110-140份、石榴110-140份、红甜菜根90-130份以及羽扇豆60-80份。
4.根据权利要求1所述的降尿酸及治疗痛风的组合物,其特征在于,按重量份计,所述组合物的制备原料包括:蜂王浆130-150份、巴西莓100-130份、宝乐果120-140份、绿咖啡豆90-130份、石榴90-130份、红甜菜根100-140份以及羽扇豆80-90份。
5.根据权利要求1所述的降尿酸及治疗痛风的组合物,其特征在于,步骤(2)所述乙醇水溶液的体积分数为50%~80%。
6.根据权利要求1所述的降尿酸及治疗痛风的组合物,其特征在于,步骤(2)中,提取料液比为1:5-1:10,提取温度50-80℃,提取时间为1-4h。
7.根据权利要求1所述的降尿酸及治疗痛风的组合物,其特征在于,步骤(3)中,提取料液比为1:8-1:20,提取温度60-90℃,提取时间为2-6h。
8.一种根据权利要求1~7任一所述的组合物在制备降尿酸或治疗痛风的食品或药物中的应用。
9.根据权利要求8所述的应用,其特征在于:所述食品为保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311574021.XA CN117547578A (zh) | 2023-11-23 | 2023-11-23 | 一种降尿酸及治疗痛风的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311574021.XA CN117547578A (zh) | 2023-11-23 | 2023-11-23 | 一种降尿酸及治疗痛风的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117547578A true CN117547578A (zh) | 2024-02-13 |
Family
ID=89822987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311574021.XA Pending CN117547578A (zh) | 2023-11-23 | 2023-11-23 | 一种降尿酸及治疗痛风的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117547578A (zh) |
-
2023
- 2023-11-23 CN CN202311574021.XA patent/CN117547578A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPWO2009093584A1 (ja) | 植物由来の高尿酸血症の予防または改善剤 | |
KR101281988B1 (ko) | 가시오가피를 함유한 숙취 해소 및 간기능 개선용 생약조성물 및 그 제조방법 | |
CN108404019A (zh) | 复方菊苣根调节嘌呤代谢紊乱的固体制品及其制备方法 | |
KR101729003B1 (ko) | 황칠 추출물 또는 황칠액 발효대사체를 포함하는 통풍 예방 또는 치료용 조성물 | |
KR101093998B1 (ko) | 숙취해소 및 간기능 개선용 기능성 조성물 | |
KR101371143B1 (ko) | 클로렐라를 유효성분으로 포함하는 간기능 개선 또는 숙취해소용 조성물 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
KR101565964B1 (ko) | 아위버섯의 물 추출물을 유효성분으로 함유하는 고지혈증 예방 또는 치료용 조성물 | |
KR101859166B1 (ko) | 인삼이 함유된 한약재 추출물을 유효성분으로 함유하는 숙취 해소용 조성물 | |
KR101870280B1 (ko) | 육계 및 육계나무의 엽병을 유효성분으로 함유하는 숙취 해소용 조성물 | |
CN117547578A (zh) | 一种降尿酸及治疗痛风的组合物及其制备方法 | |
CN108379455B (zh) | 一种降尿酸组合物 | |
KR100642801B1 (ko) | 한약재와 배 추출물을 배합한 항당뇨 식품 조성물 및 그의제조방법 | |
KR20110132887A (ko) | 간, 위 기능 및 숙취 개선용 조성물 | |
CN112057559A (zh) | 霍山石斛提取物在预防、缓解和/或治疗尿酸性肾病药物中的应用 | |
JP2006016340A (ja) | ザクロ抽出物を有効成分とする、血中尿酸値低下剤 | |
KR20150031373A (ko) | 비타민나무 잎 추출물을 유효성분으로 함유하는 비만 예방 또는 치료용 약학 조성물 및 식품 조성물 | |
CN108720013A (zh) | 一组由果糖和茶叶提取物组成的醒酒护肝的保健食品的配方及生产工艺 | |
KR102302047B1 (ko) | 엉겅퀴, 민들레, 배, 아로니아 및 꿀로 이루어진 혼합물을 함유하는 간보호 또는 숙취해소용 조성물 | |
TWI766295B (zh) | 一種草本組合物及其降尿酸、降低體脂肪及降低血糖之用途 | |
CN112933162A (zh) | 一种具有降尿酸作用的组合物及其应用 | |
KR20080041791A (ko) | 매생이 추출물을 포함하는 골다공증 예방 또는 치료용조성물 | |
TWI643632B (zh) | 蘆筍葉萃取物、其製備方法及其用途 | |
KR101761822B1 (ko) | 진지버 오피시날 추출물 및 캠페리아 파비플로라 추출물을 함유하는 관절염의 개선, 예방 또는 치료용 조성물 | |
CN118044604A (zh) | 一种用于辅助降低血糖,降低血压的诺丽果酵素组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |